Tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) significantly improve the outcomes of patients with advanced clear cell renal cell carcinoma (ccRCC); however. high-grade toxicities can occur. particularly during combination therapy. Herein. https://foldlyers.shop/product-category/poe-switches-injectors/